Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

University of Florida

Status and phase: Enrolling; Phase 4

Conditions: Hypertension, Resistant to Conventional Therapy

Treatments: Drug: Minocycline Hydrochloride; Drug: Placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT06246396

2R01HL132448-05A1 (U.S. NIH Grant/Contract)

IRB202301939

Details and patient eligibility

About

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are:

• To what extent does minocycline lower blood pressure and are these effects different across races?
• Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these?

Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

Full description

One hundred twenty patients (targeting 60 White patients and 60 Black or African American [AA] patients) with treatment-resistant hypertension will be enrolled. A total of 34 patients (17 from each treatment arm, with similar race distribution), who are participants in the main study, will also be enrolled in a substudy that includes neuroimaging. The study will last 3 months, and will include 3 visit time points (screening, randomization visit, 3-month follow-up visit).

Participants will be randomly assigned, in a 1:1 allocation, to minocycline 100 mg twice per day, or matching placebo, each provided by the study, and investigators will be blinded to treatment assignment.

At the baseline and 3-month follow-up visit, subjects will undergo:

• A comprehensive medical history and examination, including assessment of antihypertensive treatment history
• A series of behavioral activity questionnaires
• Blood tests (plasma renin activity, aldosterone, catecholamines, serum creatinine, lipid panel, hemoglobin a1c, as well as various biomarkers of immune and inflammatory activity, and gut leakiness markers)
• Urine/saliva tests for antihypertensive adherence
• Gut microbiota profiling via whole metagenomic sequencing of stool samples
• Blood pressure (BP) measurement, including unattended office BP and 24-hour ambulatory BP

Subjects enrolled in the neuroimaging substudy will also have PET/MR imaging performed at each visit. Neuroimaging activities will take place at Emory University in Atlanta, GA.

At the final visit (3-month follow-up), participants will also have blood tests to measure study drug concentration, as a measure of adherence to the assigned treatment.

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥18 years
• Self-identify as White or African American
• Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥30 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed thiazide or thiazide-like diuretic (hydrochlorothiazide ≥25 mg/day or equivalent)
• The participant agrees to have all study procedures performed

Exclusion criteria

• Known hypersensitivity or contraindication to minocycline or other tetracyclines
• Recent (≤3 months prior), ongoing, or expected use of oral antibiotics
• Estimated glomerular filtration rate (eGFR) of <45mL/min/1.73m2, using the MDRD equation
• Known secondary hypertension
• History of antihypertensive crisis, defined as any in-patient hospitalizations for antihypertensive crisis/emergency within the past year
• History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of >20 mm Hg or DBP of >10 mm Hg within 3 minutes of standing) in the past year
• History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months
• Evidence of alcoholism or drug abuse
• Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)
• Ongoing or expected use of significant BP-interfering medications (excepting oral contraceptives)
• Current pregnancy or anticipated pregnancy during the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

120 participants in 2 patient groups, including a placebo group

Minocycline Hydrochloride

Experimental group

Description:

Minocycline hydrochloride 100 mg, administered twice daily for 3 months

Treatment:

Drug: Minocycline Hydrochloride

Placebo

Placebo Comparator group

Description:

Placebo administered twice daily for 3 months

Treatment:

Drug: Placebo